Last Updated: August 24, 2026

AZMIRO Drug Patent Profile

Name: AZMIRO Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Azmiro patents expire, and when can generic versions of Azmiro launch?

Azmiro is a drug marketed by Azurity and is included in one NDA. There are three patents protecting this drug.

The generic ingredient in AZMIRO is testosterone cypionate. There are sixty-nine drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the testosterone cypionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Azmiro

A generic version of AZMIRO was approved as testosterone cypionate by PADAGIS US on January 31^st, 2005.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for AZMIRO?
What are the global sales for AZMIRO?
What is Average Wholesale Price for AZMIRO?

Summary for AZMIRO

US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	3,859
What excipients (inactive ingredients) are in AZMIRO?	AZMIRO excipients list
DailyMed Link:	AZMIRO at DailyMed

Drug patent expirations by year for AZMIRO

Pharmacology for AZMIRO

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

US Patents and Regulatory Information for AZMIRO

AZMIRO is protected by three US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	AZMIRO	testosterone cypionate	SOLUTION;INTRAMUSCULAR	216318-001	Jun 2, 2022		RX	Yes	Yes	12,138,271	⤷ Start Trial	Y			⤷ Start Trial
Azurity	AZMIRO	testosterone cypionate	SOLUTION;INTRAMUSCULAR	216318-001	Jun 2, 2022		RX	Yes	Yes	11,642,355	⤷ Start Trial	Y			⤷ Start Trial
Azurity	AZMIRO	testosterone cypionate	SOLUTION;INTRAMUSCULAR	216318-001	Jun 2, 2022		RX	Yes	Yes	11,311,554	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.